Global Fibromyalgia Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Diagnosis;

Blood Tests and Others.

By Treatment;

Medication, Therapy, and Others.

By Route of Administration;

Oral, Parenteral, and Others.

By End User;

Hospitals, Homecare, Specialty Clinics, and Others.

By Distribution Channel;

Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn488243264 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Fibromyalgia Market (USD Million), 2021 - 2031

In the year 2024, the Global Fibromyalgia Market was valued at USD 2,543.12 million. The size of this market is expected to increase to USD 4,401.01 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.2%.

The global fibromyalgia market is poised for significant growth in the foreseeable future, driven by factors such as emerging markets and substantial investments in research and development. The market is bolstered by the increasing prevalence of fibromyalgia cases worldwide and the heightened focus on research initiatives conducted by pharmaceutical companies. According to the European Network of Fibromyalgia Associations (ENFA), millions of individuals across Europe and globally are affected by fibromyalgia. Additionally, the COVID-19 pandemic has also played a significant role in shaping market dynamics.

Data Bridge Market Research anticipates a steady growth rate for the global fibromyalgia market over the forecast period. The expected compound annual growth rate (CAGR) is projected to be around 7%. The market, valued at a significant figure is expected to witness substantial expansion by the end of the forecast period. The market report compiled by the Data Bridge Market Research team offers valuable insights into various aspects such as market value, growth rate, market segments, geographical coverage, key market players, and the overall market scenario. Additionally, the report provides in-depth expert analysis, patient epidemiology, pipeline analysis, pricing trends, and regulatory framework.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain, accompanied by symptoms such as sleep disturbances, memory issues, fatigue, and mood disturbances. It is believed that fibromyalgia disrupts the brain's processing of pain signals, although the exact cause remains unclear. Factors such as genetic predisposition, chronic infections, and physical or emotional trauma are believed to contribute to the development of fibromyalgia. Females are at a higher risk of developing fibromyalgia compared to males, and conditions such as rheumatoid arthritis, osteoarthritis, or lupus may also be associated with fibromyalgia.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Diagnosis
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By End User
    5. Market Snapshot, By Distribution Channel
    6. Market Snapshot, By Region
  4. Global Fibromyalgia Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increased Incidence of Fibromyalgia

        2. Research and Development Investments

        3. Rising Demand for Oral Drugs

      2. Restraints
        1. Lack of Specific Diagnostic Tests

        2. Lack of skilled professionals

        3. High Cost

      3. Opportunities
        1. Increased Clinical Research
        2. Personalized Medicine Approaches
        3. Increasing Demand for Retail Pharmacies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Fibromyalgia Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Blood Tests
      2. Others
    2. Global Fibromyalgia Market, By Treatment, 2021 - 2031 (USD Million)
      1. Medication
      2. Therapy
      3. Others
    3. Global Fibromyalgia Market, By Route of Administration, 2021 - 2031 (USD Million)

      1. Oral

      2. Parenteral

      3. Others

    4. Global Fibromyalgia Market, By End User, 2021 - 2031 (USD Million)

      1. Hospitals

      2. Homecare

      3. Specialty Clinics

      4. Others

    5. Global Fibromyalgia Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacy
      2. Online Pharmacy
      3. Retail Pharmacy
    6. Global Fibromyalgia Market, By Geography, 2021 - 2031 (USD Million)
      1. North America

        1. United States

        2. Canada

      2. Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Nordic

        7. Benelux

        8. Rest of Europe

      3. Asia Pacific

        1. Japan

        2. China

        3. India

        4. Australia & New Zealand

        5. South Korea

        6. ASEAN (Association of South East Asian Countries)

        7. Rest of Asia Pacific

      4. Middle East & Africa

        1. GCC

        2. Israel

        3. South Africa

        4. Rest of Middle East & Africa

      5. Latin America

        1. Brazil

        2. Mexico

        3. Argentina

        4. Rest of Latin America

  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc

      2. AstraZeneca

      3. Johnson and Johnson Services Inc

      4. F. Hoffmann-La Roche Ltd

      5. Janssen Pharmaceuticals, Inc

      6. Sanofi

      7. Merck & Co., Inc

      8. Mylan N.V.

      9. Teva Pharmaceutical Industries Ltd

      10. Bristol Myers Squibb Company

      11. GlaxoSmithKline Plc

      12. Bayer AG

      13. Perrigo Company plc

      14. Sun Pharmaceutical Industries Ltd

      15. Cipher Pharmaceuticals Inc

      16. Novartis AG

  7. Analyst Views
  8. Future Outlook of the Market